The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...
Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...
A clean indoor environment can help reduce exposure to pollution. “Use an air purifier with a HEPA filter and seal windows ...
High-dose fluticasone increases sputum bacterial load in severe COPD; ICS withdrawal is poorly tolerated, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback